---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-295039"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:51:21.975297+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Reneo's mavodelpar fails Phase 3 STRIDE study; cuts workforce 70%

## Summary
- Pivotal STRIDE trial of mavodelpar in primary mitochondrial myopathies missed primary endpoint (12MWT at week 24) and key secondary.
- Company suspends all mavodelpar development including STRIDE AHEAD; workforce reduced ~70%.
- Estimated Q4 2023 charges of ~$2.5M for severance and termination-related costs.
- Company has >$100M in cash, cash equivalents, and short-term investments to fund operations.

## SEC filing metadata
- accession: 0001193125-23-295039
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312523295039/0001193125-23-295039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312523295039/d553352d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-295039
- JSON: https://secwatch.observer/filing/0001193125-23-295039.json
- Plain text: https://secwatch.observer/filing/0001193125-23-295039.txt

## Key facts
- Restructurings & Charges
  OnKure Therapeutics, Inc. announced a restructuring with charges of approximately $2.5 million.
  - Type: restructuring
  - Charge: approximately $2.5 million
  source text: the Company estimates that it will incur charges of approximately $2.5 million associated with cash severance payments and other employee termination-related costs in the fourth quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312523295039/0001193125-23-295039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.